

Clinical trials of mTOR inhibitor for advanced breast cancer (metastatic) in patient trastuzumab-resistant, and previously treated by taxanes

TrialResults-center www.trialresultscenter.org

1 add-on to anti HER-2 agent

Trial	Treatments	Patients	Trials design and methods
everolimus + trastuzumab + vinorelbine vs trastuzumab + vinorelbine alone			
BOLERO-3 , 2014 [NCT01007942] n=284/285 follow-up:	daily everolimus (5 mg/day) plus weekly trastuzumab (2 mg/kg) and vinorelbine (25 mg/m ²) in 3-week cycles versus placebo plus trastuzumab plus vinorelbine,	women with HER2-positive, trastuzumab-resistant, advanced breast carcinoma who had previously received taxane therapy	Parallel groups double-blind

References

BOLERO-3, 2014:

Andr F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Oncol* 2014;15:580-91 [[24742739](#)]

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.